HELP Stock — Cybin Inc. Common Stock

Cybin Inc. Common Stock (HELP)

Updated October 16, 2026.

HELP is a Stock. Its deepest 1-year drawdown was 55.6%.

Cybin Inc., doing business as Helus Pharma, is a clinical-stage pharmaceutical company developing therapies for psychiatric and neurological conditions, including HLP003 (a deuterated psilocybin analog in phase 3 trials for major depressive disorder) and HLP004 (a deuterated DMT compound in phase 2 trials for generalized anxiety disorder). The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotech and psychedelic medicine research, though it carries the risk profile typical of pre-revenue clinical-stage companies.

HELP performance

Returns are updating. HELP's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 55.6%.

HELP key facts

Asset type

Stock

Asset class

Equity

Inception date

09/13/2019

Distribution frequency

None

Last close

$10.55 (as of 2026-10-16)

Market cap

$770,784,815

Average volume

1310288.0

Beta

0.539

Payout ratio

0.0%

EPS

$-4.10

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HELP risks and drawbacks

The deepest 1-year drawdown on record here is 55.6%.

Who may consider HELP — and who may not

It is a weaker fit for investors who need monthly cash flow (HELP does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on HELP

• All tickers starting with H

Tagged: Healthcare.

Frequently asked questions